Today, February 4th 2022, is the 21st World Cancer Day. This international day is intended to provide information about cancer prevention options and current developments in the fields of diagnosis, therapy and aftercare.

Pharmacelsus, a company of the GBA Group Pharma, accompanies research and drug development. For more than 20 years, we have been planning, organizing and implementing customer-specific preclinical studies. Our biomarker services help to predict bioactivity, efficacy and adverse reactions of the lead compound in the early development phase and, thus, allow the selection of only promising drug candidates for the clinical phase. This is how we contribute to drug discovery and cancer therapy.

The first wave of the relocation to the Neuried facility of GBAPharmaLabs was finished successfully last week and we are preparing to welcome the local competent authority for GMP-inspection.

What started 30 years ago developed into one of the largest service providers in the field of clinical trials as a laboratory provider supporting clinical trials of phases one to four. Today LKF has more than 130 highly motivated employees working in a wide variety of areas in a highly automated surrounding. LKF will continue to stand for quality, reliability and flexibility in the future.

It is our great pleasure to announce that LKF – Laboratorium für Klinische Forschung GmbH - has reorganized the board of directors with the beginning of the new year: Dr. Gerrit Schoenicke, MD and Dr. Volker El-Samalouti have taken over the role as managing directors and, together with Bärbel Wilke, they will be responsible for the ongoing development of the company. Former managing director Uwe Troge will remain responsible as an authorized signatory.